Excellence
for life

Excellence dedicated to nuclear medicine,
healthcare and environment.

More about us

Our departments

One group, two entities

IRE, world leader in the production of radioisotopes and its prevention division, IRE Lab

Radiochemical products Analysis and services

IRE ELiT Radiopharma, a laboratory of ideas and actions for radiopharmaceutical innovation

Radiopharmaceutical products

Our figures

Our figures

IRE is one of the leaders in the production of molybdenum (99Mo) for the manufacture of technetium-99m (99mTc) generators.

IRE ELiT is one of the only two global suppliers of germanium-68 (68Ge) / gallium-68 (68Ga) generators to have been approved as a drug in Europe and as an Active Pharmaceutical Ingredient in the United States.

Our history
7MPatients

Can benefit from a medical examination each year thanks to radioisotopes produced at IRE

100MTurnoveren 2019
230Employees including
30 at IRE ELiT
15%Of turnover
reinvested in R&D

Our
values

The values of our company are the moral principles we set for ourselves in the performance of our activities. They shape our corporate culture.

Discover our values
Events
March 20
Congress
JFMN 2025

11th Francophone Days of Nuclear Medicine
May 16
Congress
BELNUC 2025

23rd Symposium of the Belgian Association of Nuclear Medicine
May 21
Congress
SEMNIM 2025

Sociedad Española de Medicina Nuclear e Imagen Molecular
June 04
Congress
SoFRa 2025

14èmes RDV de la SoFRa, Société Française de radiopharmacie
News
Discover all news
17-12-2024
IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site

Fleurus, December 17th, 2024 – The Institute for Radioelements (IRE) announces the arrival of a 30 MeV IBA cyclotron at its Fleurus site this Tuesday, December 17th, 2024. This strategic investment marks a decisive step in IRE’s commitment to expanding its production capacities and enhancing its self-sufficiency in Germanium-68 (Ge-68) production.

More information
06-06-2024
IRE ELiT and Grand Pharmaceutical Co., Ltd. announce partnership for Galli Eo (Gallium-68 generator) distribution in China

Fleurus (Belgium) and Wuhan (China), 06 June 2024, – IRE ELiT, a leading global player in the field of radiopharmaceuticals, is pleased to announce the signing of a distribution agreement with Grand Pharmaceutical (China) Co., Ltd. (“Grand Pharma”, and its subsidiary Chengdu Purevalley Medical Technology Co., Ltd.), a major pharmaceutical conglomerate, for the distribution of its Galli Eo (Gallium-68 generator) in China. This strategic partnership underscores IRE ELiT’s commitment to expanding its footprint in one of the most dynamic and rapidly growing markets for radiopharmaceuticals.

More information
28-03-2023
IRE moves to 100% LEU (Low-Enriched Uranium) conversion

Fleurus, Belgium, March 28th, 2023 – The Institute for Radioelements (IRE), world leader in the production of molybdenum-99 (Mo-99), the most widely used radioisotope in nuclear medicine for diagnosis, and iodine-131 (I-131) essential and irreplaceable radionuclide for thyroid cancer treatments, announced today the complete conversion of its production process to low-enriched uranium (LEU).

More information
13-02-2023
Ground-breaking ceremony for RECUMO

From 2026 onwards, the nuclear research centre SCK CEN will transform radioactive residues into low-enriched uranium and will purify them in its brand new RECUMO facility. These residues resulting from the production of medical radioisotopes on the site of the Institut National des Radioéléments (IRE). Today, the first sod was turned for the RECUMO building. With it, IRE and SCK CEN are literally creating a European first on Belgian soil.

More information
25-02-2022
The fight against cancer intensified thanks to SCK CEN and the IRE

SCK CEN, the Belgian Nuclear Research Centre, and the National Institute for Radioelements (IRE) are going to start the large-scale production of lutetium-177. This decision, validated today by the signature of the two partners, opens up opportunities for cancer patients. Among other things, this radioisotope is very promising for the treatment of prostate cancer. This type of cancer is responsible for 90,000 deaths each year in Europe.

More information